Citation Tools
PDFClinical/translational cancer immunotherapy
Short report
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status